Gastrodin Modulates RAS-SIRT3 in Reactive Astrocyte–Microglia Interactions

Study Background and Research Question

Neuroinflammation is a hallmark of various central nervous system (CNS) disorders, with astrocytes and microglia jointly shaping the inflammatory response. While gastrodin—an active component of Gastrodia elata—is established as neuroprotective and anti-inflammatory, its impact on astrocyte phenotype regulation and the molecular mechanisms underlying these effects remain incompletely resolved. The recently published article by Zuo et al. (Eur J Neurosci. 2024;60:3677–3693) investigates whether gastrodin modulates the interplay between microglia and astrocytes through the renin-angiotensin system (RAS)–SIRT3 pathway, and how AT1 receptor inhibition might influence these effects.

Key Innovation from the Reference Study

This study provides direct evidence that gastrodin regulates the expression of RAS components and SIRT3 in astrocytes exposed to microglial conditioned medium. Critically, the authors show that modulation of the AT1 receptor, including selective antagonism with azilsartan (TAK-536), impacts the astrocytic response to inflammatory cues. This delineates a novel mechanistic pathway by which gastrodin exerts anti-inflammatory and neurotrophic effects, with implications for targeted intervention in neuroinflammation.

Methods and Experimental Design Insights

The investigators utilized co-culture and conditioned medium models with TNC-1 astrocytes and BV-2 microglia. Microglia were pre-treated with lipopolysaccharide (LPS) to induce an activated, proinflammatory state, or with both LPS and gastrodin to assess its modulatory effects. The conditioned medium (CM) from these microglia was then applied to TNC-1 astrocytes. Key gene and protein markers—including angiotensinogen (ATO), angiotensin-converting enzyme (ACE), AT1 and AT2 receptors, SIRT3, complement C3, S100A10, and cytokines—were evaluated by RT-PCR, immunofluorescence, and western blotting.

To specifically probe the role of AT1, the authors used azilsartan, a potent and selective AT1 receptor inverse agonist, to evaluate phenotypic marker expression in astrocytes in the context of microglial-derived inflammatory signals. This approach allowed for dissection of the contribution of AT1-mediated signaling to astrocyte reactivity and phenotype switching.

Protocol Parameters

• Astrocyte-microglia model: TNC-1 astrocytes incubated with BV-2 microglia conditioned medium, ± LPS (to induce microglial activation), ± gastrodin (to test anti-inflammatory modulation).
• Gastrodin treatment: Applied to microglia prior to conditioned medium collection; dosing and timing as per reference protocol.
• Azilsartan intervention: Selective AT1 antagonist added to astrocyte cultures; concentrations aligned with established IC₅₀ (2.6 nM) for AT1 receptor blockade as characterized in the Azilsartan product information.
• Marker analysis: Expression measured via RT-PCR, immunofluorescence, and western blot for RAS components, SIRT3, C3, S100A10, and cytokines.

Core Findings and Why They Matter

Astrocytes exposed to LPS-activated microglial CM upregulated ATO, ACE, AT1, SIRT3, C3 (A1 marker), multiple proinflammatory cytokines, and neurotrophic factors, while AT2 and S100A10 (A2 marker) were downregulated. Treatment with gastrodin-modified microglial CM reduced the expression of most proinflammatory and RAS-related markers, but increased SIRT3, IGF-1, and BDNF, indicating a shift toward a neurotrophic, anti-inflammatory astrocyte phenotype. These data support the role of SIRT3 as a mediator of the neuroprotective actions of gastrodin.

Importantly, selective AT1 receptor inhibition with azilsartan suppressed C3 and S100A10 expression, further implicating AT1 signaling in the regulation of astrocyte phenotype in response to microglial activation. This connection between RAS modulation and astrocytic functional states deepens our understanding of neuroinflammatory mechanisms and identifies AT1 as a tractable target for intervention in CNS disorders characterized by glial activation.

Limitations and Transferability

While the conditioned medium model provides a robust platform to dissect astrocyte–microglia interactions, it lacks the complexity of in vivo CNS microenvironments, including vascular, neuronal, and systemic immune influences. The use of immortalized cell lines (TNC-1, BV-2) may not fully recapitulate primary glia biology. Additionally, although gastrodin and azilsartan effects were clear at the molecular level, functional in vivo outcomes and relevance to chronic neurodegenerative processes require further validation.

Why this cross-domain matters, maturity, and limitations

This research bridges RAS pharmacology—traditionally focused on cardiovascular regulation—with neuroinflammation and glial biology. The demonstration that AT1 antagonism modulates astrocyte phenotype via microglial signaling suggests that molecules like azilsartan, previously used predominantly in cardiovascular research, may have translational value in CNS disease models. However, the maturity of this cross-domain application is still at a preclinical, mechanistic stage; clinical implications remain speculative until corroborated by animal and human studies.

Research Support Resources

For laboratories investigating RAS-linked neuroinflammatory pathways, selective AT1 antagonists are critical reagents. Azilsartan (TAK-536, SKU B2210) is a well-characterized, high-purity AT1 inverse agonist with an IC₅₀ of 2.6 nM and validated utility in models involving astrocyte and microglia activation, as supported by the present study. Researchers can incorporate Azilsartan into astrocyte–microglia co-culture or conditioned medium protocols to further dissect RAS mechanisms in CNS inflammation.